Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

PURPOSE: The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to 15%. We previously reported that adoptive cell therapy (ACT) with autologous antitumor lymphocytes in lymphodepleted hosts mediated objective res...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Dudley, Mark E., Yang, James C., Sherry, Richard, Hughes, Marybeth S., Royal, Richard, Kammula, Udai, Robbins, Paul F., Huang, JianPing, Citrin, Deborah E., Leitman, Susan F., Wunderlich, John, Restifo, Nicholas P., Thomasian, Armen, Downey, Stephanie G., Smith, Franz O., Klapper, Jacob, Morton, Kathleen, Laurencot, Carolyn, White, Donald E., Rosenberg, Steven A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2008
Soggetti:
Immunotherapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2652090/
https://ncbi.nlm.nih.gov/pubmed/18809613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.5449
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi